Prostate Cancer Foundation is located in Santa Monica, CA. The organization was established in 1993. According to its NTEE Classification (T20) the organization is classified as: Private Grantmaking Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. As of 12/2023, Prostate Cancer Foundation employed 46 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Prostate Cancer Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Prostate Cancer Foundation generated $57.3m in total revenue. This represents relatively stable growth, over the past 5 years the organization has increased revenue by an average of 4.9% each year. All expenses for the organization totaled $55.1m during the year ending 12/2023. While expenses have increased by 2.9% per year over the past 5 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2020, Prostate Cancer Foundation has awarded 134 individual grants totaling $92,127,448. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
PCF IS THE LEADING PHILANTHROPIC ORGANIZATION FUNDING HIGH RISK & REWARD PROSTATE CANCER RESEARCH.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE PCF RESEARCH ENTERPRISE IS A PEER-REVIEW RESEARCH FUNDING PROGRAM THAT PROVIDES FUNDING TO 3300 SCIENTISTS CONDUCTING INNOVATIVE RESEARCH PROJECTS AT MORE THAN 255 LEADING CANCER CENTERS AND UNIVERSITIES. PRIORITY IS GIVEN TO HIGH-RISK, HIGH-RETURN PROJECTS WITH THE GREATEST POTENTIAL TO IMPROVE SURVIVAL AND THE OVERALL QUALITY OF LIFE FOR MEN WITH PROSTATE CANCER. THE CORNERSTONE OF THE PCF RESEARCH ENTERPRISE IN 2023 WAS OUR CHALLENGE AWARDS PROGRAM AND NEW TACTICAL AWARDS PROGRAM, WHICH SUPPORT CROSS-DISCIPLINARY TEAMS OF INVESTIGATORS CONDUCTING PIONEERING RESEARCH TO ADDRESS CRITICAL UNMET MEDICAL NEEDS FOR PROSTATE CANCER PATIENTS. IN 2023, PCF FUNDED 19 MULTI-YEAR TEAM RESEARCH PROJECTS THAT EACH OFFER HIGH POTENTIAL FOR IMPROVED DETECTION, ENHANCED QUALITY OF LIFE AND HIGHER SURVIVAL RATES.
MORE THAN 12,000 MEN CARED FOR BY THE DEPARTMENT OF VETERANS AFFAIRS (VA) HOSPITALS ARE NEWLY DIAGNOSED WITH PROSTATE CANCER EACH YEAR, MAKING IT THE MOST FREQUENTLY DIAGNOSED CANCER AMONG VETERANS. THE PCF-VA PARTNERSHIP IS EXPANDING RESEARCH INTO PROSTATE CANCER PRECISION ONCOLOGY TREATMENT OPTIONS. THE COLLABORATION IS EXPANDING THE NUMBER OF PRECISION ONCOLOGY CLINICAL STUDIES CONDUCTED AT VETERANS HEALTH ADMINISTRATION HOSPITALS, ENSURING THAT ELIGIBLE VETERANS CAN ACCESS AND PARTICIPATE IN THESE STUDIES. THE VA'S PRECISION ONCOLOGY PROGRAM FOR CANCER OF THE PROSTATE (POPCAP) WAS ESTABLISHED IN PARTNERSHIP WITH THE PROSTATE CANCER FOUNDATION 2016. THE PROGRAM USES GENETIC TESTING TO FIND THE BEST POSSIBLE TREATMENTS FOR VETERANS WITH ADVANCED PROSTATE CANCER. POPCAP'S NETWORK EXTENDS ACROSS THE U.S. IT INCLUDES 21 PRECISION ONCOLOGY CENTERS OF EXCELLENCE, SUPPLEMENTED BY REGIONAL CENTERS, THAT PROVIDE CANCER CARE TO ANY VETERAN WHO DEVELOPS PROSTATE CANCER, NO MATTER WHERE HE LIVES.
FOR MORE THAN 3 MILLION AMERICAN MEN AND THEIR FAMILIES FIGHTING PROSTATE CANCER AND MILLIONS MORE GLOBALLY, PCF SERVES AS A PRIMARY SOURCE FOR NEW STANDARD-OF-CARE AND RESEARCH INFORMATION. PCF EDUCATES THE PUBLIC ABOUT PROSTATE CANCER RISKS, SCREENING, PREVENTION, TREATMENT OPTIONS, AND SIDE EFFECTS. WE CONNECT PATIENTS, LOVED ONES, CARE PROVIDERS, AND SCIENTISTS TO CRITICAL UPDATES, THE LATEST DEVELOPMENTS, BEST PRACTICES, AND NEWS FROM THE TREATMENT PIPELINE. SINCE PCF'S INCEPTION, AND THROUGH ITS EFFORTS, PATIENTS AROUND THE WORLD ARE LIVING LONGER, SUFFERING FEWER COMPLICATIONS, AND ENJOYING BETTER QUALITY OF LIFE. PCF AIMS TO SPUR MEN AND WOMEN ALIKE TO TALK ABOUT THIS DISEASE, TO UNDERSTAND ITS URGENCY, AND TO HAVE INFORMATION-DRIVEN HOPE.
PCF CREATED THE YOUNG INVESTIGATOR AWARD PROGRAM WITH ONE GOAL: TO BUILD A GIFTED COHORT OF HUMAN CAPITAL SUPPORTING THE NEXT GENERATION OF PROSTATE CANCER RESEARCHERS. AWARDS ARE MADE TO EARLY-CAREER SCIENTISTS WORKING IN A RESEARCH ENVIRONMENT CAPABLE OF SUPPORTING HIGH-IMPACT PROSTATE CANCER RESEARCH, DRAWN FROM A VARIETY OF MEDICAL RESEARCH DISCIPLINES. SINCE 2007, PCF HAS AWARDED NEARLY $88 MILLION TO ADVANCE THE EARLY CAREERS OF 408 PCF YOUNG INVESTIGATORS, ENSURING A CONTINUED STREAM OF HUMAN CAPITAL INTO OUR RESEARCH COMMUNITY. THE PCF YOUNG INVESTIGATOR PROGRAM PLAYS AN INTEGRAL ROLE IN CHAMPIONING, MENTORING, AND IDENTIFYING FUTURE MEDICAL RESEARCH PROGRAM LEADERS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Charles Ryan CEO | Officer | 60 | $721,046 |
Gina Carithers Evp, President | OfficerTrustee | 50 | $624,635 |
Howard Soule Evp, Chief Science Officer | Officer | 50 | $582,696 |
William Oh Evp, Chief Medical Officer | Officer | 50 | $551,617 |
Helen Hsieh Evp, Finance | Officer | 50 | $359,883 |
Kari J Kalstad Vp, Operations | 50 | $274,286 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Vision Matrix Productions Inc Event Productions | 12/30/23 | $1,516,269 |
Boulle Event Management Outreach Program Mgmt | 12/30/23 | $196,665 |
Helmsbriscoe Resourceone Event Management | 12/30/23 | $113,380 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $2,364,698 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $52,523,215 |
Noncash contributions included in lines 1a–1f | $1,159,796 |
Total Revenue from Contributions, Gifts, Grants & Similar | $54,887,913 |
Total Program Service Revenue | $4,555 |
Investment income | $2,395,709 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $2,918 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $57,291,095 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $22,879,313 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $6,963,914 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $3,385,716 |
Compensation of current officers, directors, key employees. | $115,453 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $5,378,610 |
Pension plan accruals and contributions | $144,368 |
Other employee benefits | $994,728 |
Payroll taxes | $424,742 |
Fees for services: Management | $970,450 |
Fees for services: Legal | $28,151 |
Fees for services: Accounting | $70,000 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $14,006 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $607,966 |
Advertising and promotion | $1,054,498 |
Office expenses | $1,267,850 |
Information technology | $463,589 |
Royalties | $0 |
Occupancy | $603,962 |
Travel | $742,209 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $8,192,602 |
Interest | $51,873 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $497,754 |
Insurance | $136,067 |
All other expenses | $14,698 |
Total functional expenses | $55,134,763 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $372,305 |
Savings and temporary cash investments | $50,418,907 |
Pledges and grants receivable | $35,951,714 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $472,884 |
Net Land, buildings, and equipment | $480,202 |
Investments—publicly traded securities | $701,140 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $3,302,938 |
Other assets | $70,888 |
Total assets | $91,770,978 |
Accounts payable and accrued expenses | $2,167,880 |
Grants payable | $39,330,540 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $1,739,373 |
Other liabilities | $550,760 |
Total liabilities | $43,788,553 |
Net assets without donor restrictions | $41,647,013 |
Net assets with donor restrictions | $6,335,412 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $91,770,978 |
Over the last fiscal year, Prostate Cancer Foundation has awarded $22,876,813 in support to 28 organizations.
Grant Recipient | Amount |
---|---|
MD ANDERSON CANCER CENTER PURPOSE: CANCER RESEARCH | $6,450,000 |
UNIVERSITY OF CALIFORNIA SAN FRANCISCO PURPOSE: CANCER RESEARCH | $2,546,665 |
JOHNS HOPKINS UNIVERSITY PURPOSE: CANCER RESEARCH | $2,300,000 |
BRONX VETERANS MEDICAL RESEARCH FOUNDATION PURPOSE: CANCER RESEARCH | $1,417,233 |
UNIVERSITY OF MICHIGAN PURPOSE: CANCER RESEARCH | $1,224,417 |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI HOSPITAL PURPOSE: CANCER RESEARCH | $1,225,000 |